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High-dose therapy with autologous stem cell support is increas-
ingly administered to patients with high-risk breast cancer.
According to a recent survey, 5886 patients with breast cancer
received high-dose therapy with stem cell support in North
America between 1989 and 1995 (Antman et al, 1997). The use of
peripheral blood stem cells (PBSC), rather than bone marrow, and
improvements in the supportive care significantly reduced the
toxicity of high-dose therapy, resulting in a decrease of the 100-
day mortality from 22% in 1989 to 5% in 1995. Instead of admin-
istering a single cycle of high-dose therapy, dose intensification
can also be achieved by administering two or more cycles of
PBSC-supported dose-escalated therapy (Dunphy et al, 1990;
Ayash et al, 1994; Broun et al, 1995; Bitran et al, 1996; Haas et al,
1997). As a consequence of the substantial decrease with regard to
morbidity and mortality, high-dose chemotherapy became a thera-
peutic option for patients with locally advanced breast cancer
(Peters et al, 1993; van der Wall et al, 1995; Gianni et al, 1997;
Haas et al, 1997; Somlo et al, 1997). For instance, in patients with
primary breast cancer and tumour involvement of more than nine
axillary lymph nodes, Gianni et al (1997) compared the efficacy of
doxorubicin followed by cyclophosphamide, methotrexate and 5-
fluorouracil to high-dose therapy with sequential administration
of cyclophosphamide, vincristine, methotrexate, cisplatin and
melphalan followed by bone marrow or PBSC transplantation. For
the 67 patients treated with high-dose therapy, the probability of
disease-free survival after 5 years was 57% compared with 41%
for those who had received cytotoxic chemotherapy at conven-
tional doses.
In this study, we report on 85 patients with high-risk stage II/III
breast cancer, including 71 patients with more than nine tumour-
positive axillary lymph nodes. Particular emphasis was put on the
evaluation of prognostic factors such as stage of the disease,
number of involved axillary lymph nodes, the hormone receptor
status, and the presence of isolated tumour cells in samples from
bone marrow obtained after high-dose therapy.
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Summary We report on the efficacy and toxicity of a sequential high-dose therapy with peripheral blood stem cell (PBSC) support in 85
patients with high-risk stage II/III breast cancer. There were 71 patients with more than nine tumour-positive axillary lymph nodes. An
induction therapy of two cycles of ifosfamide (total dose, 7.5 g m–2) and epirubicin (120 mg m–2) was given, and PBSC were harvested during
G-CSF-supported leucocyte recovery following the second cycle. The PBSC-supported high-dose chemotherapy consisted of two cycles of
ifosfamide (total dose, 12 000 mg m–2), carboplatin (900 mg m–2) and epirubicin (180 mg m–2). Patients were autografted with a median
number of 3.7 ´ 106 CD34+ cells kg–1 (range, 1.9–26.5 ´ 106) resulting in haematological reconstitution within approximately 2 weeks following
high-dose therapy. The toxicity was moderate in general, and there was no treatment-related toxic death. Twenty-one patients relapsed
between 3 and 30 months following the last cycle of high-dose therapy (median, 11 months). The probability of disease-free and overall
survival at 4 years were 60% and 83%, respectively. According to a multivariate analysis, patients with stage II disease had a significantly
better probability of disease-free survival (74%) in comparison to patients with stage III disease (36%). The probability of disease-free survival
was also significantly better for patients with oestrogen receptor-positive tumours (70%) compared to patients with receptor-negative ones
(40%). Bone marrow samples collected from 52 patients after high-dose therapy were examined to evaluate the prognostic relevance of
isolated tumour cells. The proportion of patients presenting with tumour cell-positive samples did not change in comparison to that observed
before high-dose therapy (65% vs 71%), but a decrease in the incidence and concentration of tumour cells was observed over time after high-
dose therapy. This finding was true for patients with relapse and for those in remission, which argues against a prognostic significance of
isolated tumour cells in bone marrow. In conclusion, sequential high-dose chemotherapy with PBSC support can be safely administered to
patients with high-risk stage II/III breast cancer. Further intensification of the therapy, including the addition of non-cross resistant drugs or
immunological approaches such as the use of antibodies against HER-2/NEU, may be envisaged for patients with stage III disease and
hormone receptor-negative tumours.
Keywords: breast cancer; high-dose chemotherapy; peripheral blood stem cell transplantation; prognostic indicators; tumour cells
1500
British Journal of Cancer (1999) 79(9/10), 1500–1507
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0239
Received 28 May 1998
Revised 11 September 1998
Accepted 25 September 1998
Correspondence to: S Hohaus, Department of Internal Medicine V, University
of Heidelberg, Hospitalstr. 3, 69115 Heidelberg, GermanyAdjuvant high-dose chemotherapy for breast cancer 1501
British Journal of Cancer (1999) 79(9/10), 1500–1507 © Cancer Research Campaign 1999
PATIENTS AND METHODS
Patients
Between July 1993 and August 1997, 85 female patients with
primary breast cancer were enrolled onto this study and completed
high-dose therapy by 31 December 1997. Their median age was 45
years (range, 23–59 years). According to the TNM classification,
52 patients had stage II and 33 patients had stage III disease. Fifty-
seven patients underwent mastectomy, while 28 had breast-
conserving surgery. The common denominator for including them
into our study was the presence of high-risk factors. The majority
of patients (71 of 85 patients) had tumour involvement of more
than nine axillary lymph nodes, while 14 patients had a median of
seven lymph nodes with additional risk factors such as hormone
receptor-negative tumour, young age, high S phase, or tumour
cells in the bone marrow. The patients were enrolled within 4
weeks after operation for the adjuvant treatment protocol. Patient
characteristics including the number of axillary lymph nodes
involved, stage of the disease and hormone receptor status are
given in Tables 1 and 2. The study was conducted under the
guidelines of the Joint Ethical Committee of the University of
Heidelberg. Each patient gave her informed consent to participate
in the study. The cut-off date of this report was 30 March 1998.
Cytotoxic chemotherapy
Cytotoxic chemotherapy consisted of two cycles of ifosfamide,
2500 mg m–2as 20-h intravenous (i.v.) infusion on 3 days, and epiru-
bicin, 40 mg m–2 as a 4-h i.v. infusion on 3 days (Figure 1). Mesna
was given at the same dose as ifosfamide on 4 days. Both cycles
were supported with R-metHuG-CSF (filgrastim, 300 mg/ day–1
Table 1 Patient characteristics
No. of patients 85
Age, years
Median 45
Range 23–59
Menopausal status
pre- 60
post- 25
Type of surgical procedure
Mastectomy 57
Breast-conserving surgery 28
Stage
II A 20
II B 32
III A 24
III B 9
No. of axillary involved lymph nodes
< 10 14
10–14 32
15–19 14
> 19 25
Receptor status
ER-positive 49 PR-positive 48
ER-negative 33 PR-negative 34
n.a. 3 n.a. 3
No., number; n.a., not available; ER, oestrogen receptor, PR, progesterone
receptor.
Table 2 Patient characteristics according to TNM stage
T1 T2 T3 T4
N1 20 32 10 8a
N 24641
a3 patients with inflammatory breast cancer. The lightly shadowed area 
denotes the 24 patients with stage III A, the darker area  stage III B
disease.
Leukaphereses Transplantation Radiotherapy
Breast-conserving
surgery: 25 of 28 patients
Mastectomy: 33 of 57 patients
Ifosfamide 7.5 g m–2
Epirubicin 120 mg m–2
G-CSF 300 mg
Ifosfamide 12 g m–2
Epirubicin 180 mg m–2
Carboplatin 900 mg m–2
85
patients
79
patients
Hormonal
therapy
pre- Goserelin
menopausal
post- Tamoxifen
2 years
5 years
Figure 1 Treatment plan1502 S Hohaus et al
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subcutaneously (s.c.); Neupogen®, Amgen Inc., Thousand Oaks,
CA, USA). The growth factor was given to shorten the period of
neutropenia and to increase the number of circulating progenitor
cells during marrow recovery.
PBSC collection began when a distinct population of CD34+
cells was measurable in the peripheral blood. The leukaphereses
were performed using a Fenwal CS3000 (Baxter Deutschland
GmbH, Munich, Germany) or a Spectra (Cobe Laboratories,
Lakewood, CA, USA). Between 10 l and 20 l were processed at
flow rates of 70–150 ml min–1. For PBSC collection, the patients
received large-bore catheters in the jugular vein as previously
described (Hahn et al, 1995).
The cytotoxic therapy was continued with two cycles of PBSC-
supported high-dose ifosfamide (total dose of 12 000 mg m–2),
epirubicin (180 mg m–2) and carboplatin (900 mg m–2) (Figure 1).
The dose of all drugs was delivered over a period of 5 days.
Ifosfamide was given as 24-h continuous i.v. infusion, while epi-
rubicin and carboplatin were administered over 4 and 2 h, respec-
tively. Mesna was given at the same dose as ifosfamide, on days
1–5, followed by an additional administration of 50% of the dose
on day 6.
PBSC were re-infused following 1 day after the end of cytotoxic
chemotherapy, and no cytokines were given following transplanta-
tion. The patients received prophylactic antimicrobial therapy with
ciprofloxacin (1000 mg day–1) and fluconazole (400 mg day–1).
Empirical antibiotic therapy was administered for fever ³ 38.5°C.
Platelet counts above 20 ´ 109 l–1 were maintained by platelet
transfusions, and packed red cells were given when the haemo-
globin was less than 8.0 g dl–2.
Pre-menopausal women received anti-hormonal therapy with
goserelin at a dose of 3.6 mg administered subcutaneously once
per month. By starting ovarian suppression from day 0 on, we
intended to suppress menstrual bleeding during the time of throm-
bocytopenia after high-dose therapy. Post-menopausal women
received tamoxifen orally at a daily dose of 30 mg which was
commenced 6 weeks following PBSC-supported high-dose
therapy. The therapy with goserelin was scheduled for 2 years,
while tamoxifen was envisaged for 5 years.
Twenty-five of 28 patients who underwent breast-conserving
surgery received local-regional irradiation of the breast and
draining lymph nodes at a dose of 50 Gy with a boost of 10 Gy to
the tumour bed. For patients undergoing modified radical mastec-
tomy, there was no general recommendation for radiotherapy of
the chest wall at the beginning. From August 1996, irradiation of
the chest wall and draining lymph nodes was included for all
patients. As a result, 33 of 57 mastectomized patients underwent
local radiotherapy.
Immunofluorescence staining and flow cytometry
For immunofluorescence analysis, 1 ´ 106 mononuclear cells
(MNC) of the leukapheresis product or between 20 and 50 ml of
whole blood (EDTA) were incubated for 30 min at 4°C with the
phycoerythrin (PE)- or fluorescein isothiocyanate (FITC)-conju-
gated monoclonal antibody (mAb) CD34 (HPCA-2) and CD45
(HLe-1) FITC. The mAbs were obtained from Becton-Dickinson
(Heidelberg, Germany). Isotype-identical antibodies served as
controls: IgG1, IgG2a (FITC/PE-conjugated, Becton-Dickinson,
Heidelberg, Germany). The cells were analysed with a Becton-
Dickinson FACScan as previously described (Hohaus et al, 1993;
Haas et al, 1994).
Immunocytochemistry
Leukapheresis products and bone marrow specimens were exam-
ined for tumour cells using an immunostaining method as previ-
ously described (Haas et al, 1997; Hohaus et al, 1997). Briefly, 1 ´
106 mononuclear cells were transferred onto glass slides using a
cytocentrifuge (Universal-16, Hettich, Tuttlingen, Germany).
Slides were fixed after air drying with formalin 3.7% (15 min) and
methanol 100% (5 min). The slides were stored at –70°C in conser-
vation medium (0.25 M saccharose, 3 mM magnesium chloride,
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50% glycerin). Immunostaining was performed using a cocktail of
four monoclonal epithelial-specific antibodies. The antibody 5D3
(BioGenex, San Ramos, CA, USA) recognizes a common epitope
on the intracellular cytokeratin components 8, 18 and 19, while the
antibody HEA 125 (Progen Biotechnik GmbH, Heidelberg,
Germany) reacts with a human surface glycoprotein specific for
epithelial cells. BM7 and BM8 are murine monoclonal antibodies
developed by S Kaul with a specificity for glycosylated side-chains
of the breast mucin encoded by the Muc1 gene. The antibody reac-
tion was developed with an alkaline–phosphatase anti-alkaline–
phosphatase method (APAAP) (Dako, Glostrup, Denmark). Four
slides containing 4 ´ 106 cells were examined per specimen.
Statistical analysis
Overall survival and disease-free survival were examined as clin-
ical outcome variables. Overall survival was defined as the time
from last blood stem cell transplantation to death. Disease-free
survival was defined as the time from last blood stem cell trans-
plantation to relapse or death. Survival curves were estimated
using the Kaplan–Meier product limit method (Kaplan et al,
1958). The univariate and multivariate analyses were performed to
identify risk factors associated with overall and disease-free
survival. Differences between the survival curves were compared
using the log-rank test (Peto et al, 1972). Multivariate analysis was
performed using the Cox regression model with stepwise analysis
(P-values for entry = 0.15 and for removal = 0.05) (Cox et al,
1972). The following risk factors were first examined in a
univariate analysis using the log-rank test: age, menopausal status,
type of surgical procedure, stage (stage II A or B versus stage III A
or B), number of tumour-positive axillary lymph nodes (group
1 < 10, group 2 10–19, group 3 > 19), histological grading (G2
versus G3), oestrogen receptor (ER) status, progesterone receptor
(PR) status, radiation therapy. In a second step, variables that were
significant in the univariate analysis were included in a multi-
variate analysis as stated above. Differences in the tumour cell
concentration of bone marrow samples obtained from the same
patient at different time points after high-dose therapy were tested
by using the Student’s paired t-test. The Student’s t-test was
performed using the Excel software (Version 6.0), while the other
statistical computations were performed using the statistical soft-
ware package SAS, Version 6.11 (SAS Institute Inc., 1995).
RESULTS
High-dose therapy with PBSC support
Eighty-five patients with high-risk stage II/III breast cancer were
enrolled onto the study to receive PBSC-supported sequential
high-dose therapy. The treatment was completed as scheduled in
79 patients, while six patients were withdrawn following the first
cycle of high-dose therapy. The reasons for discontinuation were
severe enterocolitis of unknown aetiology in two patients, cardiac
toxicity with T-wave changes indicative for ischaemic heart
disease in one patient and central nervous system (CNS) toxicity
in two patients. There was one patient who declined the second
cycle because of severe anxiety. The time interval between the two
cycles of high-dose therapy varied between 4 and 15 weeks
(median, 7 weeks). In one patient with allo-reactive antibodies
against platelets, the second cycle was postponed until appropriate
histocompatibility leucocyte antigen (HLA)-cross-match negative
donors were found for platelet donations.
High-dose therapy was supported with a median number of
3.8  ´ 106 CD34+ cells kg–1 (range, 1.9–26.5 ´ 106) which were mainly
collected following the second cycle of granulocyte colony-stimulating
factor (G-CSF)-supported induction therapy. Considering a threshold
number of 2.5 ´ 106 CD34+ cells kg–1 as adequate amount for
sustained engraftment, the sequential high-dose therapy could be
supported with portions of a single leukapheresis (LP) product in 45%
of the patients, while the percentage of patients requiring between three
and six LP products was only 14%.
One hundred and thirty-three LP products collected from 65
patients were assessed for the presence of tumour cells using an
immunocytochemical staining method. There were only 12
patients (18%) with harvests containing tumour cells at a concen-
tration between 0.25 and 1.25/106 mononuclear cells. In contrast,
71% of bone marrow specimens obtained from 49 patients before
high-dose therapy harboured tumour cells.
The time needed for haematological reconstitution following
both cycles of high-dose therapy was not different. A neutrophil
count of 0.5 ´ 109 l–1 was observed after a median time of 13 days
Table 3 Toxicity of PBSC-supported high-dose therapy
Cycle 1 Cycle 2
No. of patients with
Fever ³ 38.5°C 76 (89%) 60 (76%)
i.v. nutrition 29 (34%) 21 (27%)
Days of
Fever ³ 38.5°C 2 (0–12) 2 (0–6)
i.v. antibiotics 7 (0–17) 7 (0–16)
i.v. nutrition 0 (0–14) 0 (0–14)
Hospital stay 14 (10–14) 13 (9–20)
Post-transplantation
No. of transfusions per patient
Red blood cells 2 (0–10) 2 (0–6)
Platelets 2 (1–18) 2 (0–6)
PBSC, peripheral blood stem cells; No., number; i.v., intravenous.
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Figure 3 Overall survival (OS) and disease-free survival (DFS) following
the last cycle of adjuvant PBSC-supported high-dose chemotherapy in 85
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(range, 8–18 days), and an unsupported platelet count of 20 ´ 109
l–1 was reached after 9 days (range, 1–20) (Figure 2). The non-
haematological toxicity was generally moderate. In particular,
there was no day-100 treatment-related mortality. Thirty percent of
the patients required total parenteral nutrition due to severe
mucositis, while the median number of days with fever of ³38.5°C
following both cycles was 2 days. As a result, the number of days
of i.v. antibiotic therapy amounted to a median of 7 days (Table 3).
Therapeutic outcome
Twenty-one patients relapsed between 3 and 30 months following
the last cycle of high-dose therapy (median, 11 months). As shown
in Table 4, the sites of relapse were similar to those reported for
patients who had received cytotoxic chemotherapy at conventional
doses. Three of 27 patients who did not receive irradiation had
local-regional relapse. In contrast, among 58 patients who under-
went local-regional radiotherapy, there was only one patient with
local relapse, which was accompanied by metastases to the lung.
There were also two patients who developed tumours in the
contralateral breast, after 5 and 7 months post-transplantation,
respectively. As a result of surgery and radiotherapy, five of the six
patients with local relapse or tumours at the contralateral site are
disease-free between 1.5 and 44 months. One patient with
hepatitis-C died of liver failure due to a hepatocellular carcinoma
21 months post-transplantation. The corresponding Kaplan–Meier
estimate for disease-free survival at 4 years following the last
cycle of high-dose therapy was 60%, while the probability of
overall survival was 83% (Figure 3).
Prognostic factor
By univariate analysis, the risk of relapse for patients with stage II
disease was significantly smaller in comparison to patients with
stage III disease (P = 0.0044). Similarly, the risk of relapse was
also significantly reduced for patients with ER-positive tumours
(P = 0.0001) when compared to patients with negative tumours.
According to the multivariate analysis, the stage of disease and the
ER-status were independent prognostic factors. As a consequence,
patients with stage II disease had a Kaplan–Meier estimate of
disease-free survival at 3 years of 74% in comparison to 36% for
patients with stage III disease (Figure 4A). In the same line, the
probability of disease-free survival was significantly better for
patients with ER-positive tumours in comparison to those with
receptor-negative ones (70% vs 40%) (Figure 4B).
Tumour cells in bone marrow samples following PBSC
In 52 patients, bone marrow samples were collected after high-
dose therapy to look for isolated tumour cells. The median time
elapsed between the last cycle of high-dose therapy and the first
examination was 4.5 months (range, 1–32 months) (Figure 5).
In 34 of 52 patients (65%) the bone marrow samples contained
tumour cells at a concentration between 0.25 and 33 cells/106
mononuclear cells (median, 2 cells/106).
The concentration of tumour cells in bone marrow specimens
decreased in the course of time which had elapsed since the end of
high-dose therapy (Figure 5A). An intraindividual examination
including 25 patients from whom bone marrow samples were
obtained on at least two occasions, showed a significant decrease
of the tumour cell concentration in 16 patients and disappearance
below detection limit in five patients (P < 0.05) (Figure 5B). Four
patients had repeatedly negative samples, while there were also
five patients presenting with a median increase of 0.5 tumour
cells/106 MNC.
Table 4 Sites of relapse
Local-regional 3
Contralateral breast 2
Bone 4
Lung 1
Liver 3
CNS 3
Multiple 5
CNS, central nervous system.
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It was interesting to note that the concentration of tumour cells
and their changes over time were not different between the patients
who relapsed and those who were disease-free (Figure 5B). In
particular, patients with relapse had a median number of 1.5
tumour cells/106 MNC, and in four of five patients even a decrease
in the concentration of tumour cells could be observed on the
occasion of a second follow-up visit.
DISCUSSION
Following conventional cytotoxic chemotherapy, long-term
disease-free survival is only achieved in 15–30% of the patients
with primary breast cancer and tumour involvement of more than
nine axillary lymph nodes (Valagussa et al, 1978; Fisher et al,
1984). As a consequence, high-dose therapy has been envisaged to
improve the treatment results for this particular group of patients.
Dose escalation in the adjuvant setting appears to be acceptable as
a result of better supportive care which also includes the use of
PBSC rather than bone marrow for autografting (Antman et al,
1997; Haas et al, 1997). The toxicity data of our study support this
notion. Following a total of 164 cycles of high-dose therapy with
ifosfamide, epirubicin and carboplatin administered to 85 patients,
there was no treatment-related toxic death, while the treatment had
to be discontinued after the first cycle of high-dose therapy in only
7% of the patients. As a result of the relatively moderate toxicity,
the high-dose therapy will be administered in an outpatient setting
for patients with a care giver.
The treatment resulted in a probability of disease-free survival
of 60% at 4 years following the last cycle of high-dose therapy.
The data are similar to those reported by other groups and suggest
that high-dose therapy may be superior to cytotoxic chemotherapy
at conventional doses (Gianni et al, 1997). Still, a significant
proportion of patients treated with high-dose therapy is at risk for
relapse and these patients eventually die of progressive disease.
We therefore looked for prognostic factors associated with an
increased risk of relapse. By multivariate analysis, stage III
disease and ER-negativity were independent prognostic factors
associated with an increased risk of relapse. This finding is in line
with data of Somlo et al (1997) showing that patients with stage III
B disease had a greater likelihood of relapse compared to patients
with stage II disease. Similar to our data, the lack of hormone
receptor expression was also associated with bad prognosis. Since
the presence of oestrogen receptors is also associated with
response to anti-hormonal treatment, the better disease-free
survival observed in patients with ER-positive tumours may also
reflect the efficacy of the anti-hormonal treatment that we admin-
istered post-transplantation. Gianni et al (1997) observed a better
disease-free survival in patients presenting with 10–20 tumour-
positive axillary lymph nodes in comparison to patients with more
than 20 lymph nodes, a finding that we could not confirm in our
patient cohort.
The relevance of radiotherapy has also to be addressed. We
observed local-regional relapses in three of 24 patients who under-
went mastectomy without receiving radiotherapy thereafter. In
contrast, among 58 patients with local-regional irradiation, there
was only one patient presenting with a local relapse and lung
metastases. These data suggest that patients with locally advanced
breast cancer are still at risk for local relapse despite the high-dose
therapy. Apparently they benefit from involved-field radiotherapy
which is accompanied by moderate toxicity (Marks et al, 1992;
van der Wall et al, 1996).
In principle, relapses following PBSC-supported adjuvant
therapy could result from reinfusion of tumour cells contained
within the autograft or from resistant tumour cells in vivo. Isolated
tumour cells in leukapheresis products were found in 18% of the
patients. Still, the proportion of patients who developed a relapse
following autografting with tumour cell-positive harvests was
similar to the relapse rate in patients who received an autograft free
of tumour cells. In any case, before high-dose therapy the incidence
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Figure 5 Detection of tumour cells in bone marrow samples obtained after
the last cycle of PBSC-supported high-dose chemotherapy. Patients who are
disease-free are symbolized by open diamonds and patients with relapse
by closed diamonds. (A) The proportion of patients with negative or
small numbers of tumour cells increases during the course of time.
(B) Concentration of tumour cells at first (52 patients) and second (25
patients) examination after high-dose therapy. In 16 of the 25 patients
permitting an intra-individual comparison, a decrease in the concentration of
the tumour cells could be observed. Four patients had repeatedly negative
samples, while five patients showed an increaseof positive samples and the concentration of tumour cells were
smaller in leukapheresis products than in bone marrow specimens.
This finding is in line with data reported by Ross et al (1993).
We also looked for tumour cells in bone marrow samples
obtained after high-dose therapy to evaluate the prognostic signifi-
cance of isolated tumour cells. It was remarkable that 65% of the
patients harboured tumour cells in the bone marrow following
PBSC-supported high-dose therapy. Still, a significant decrease in
the concentration of tumour cells was observed on the occasion of
further follow-up visits. The prognostic relevance of our finding is
not clear at the moment, as the median concentration of tumour
cells in the bone marrow at the first examination and the reduction
noted at follow-up visits were not different between patients with
relapse and those who were disease-free. This finding suggests that
isolated tumour cells in the bone marrow may not reflect the fate of
disseminated tumour cells in other organs such as lung or liver.
These are preferred sites for metastases, suggesting that the bone
marrow may not provide the appropriate micro-environment for
the growth of epithelial tumour cells. This is different from the
malignant cells in patients with haematological malignancies. For
instance, patients with chronic myeloid leukaemia who have low,
decreasing or undetectable levels of BCR-ABL RNA expression
have a reduced risk of relapse, while patients with increasing levels
of BCR-ABL RNA are at increased risk (Lin et al, 1996). Similarly,
persistence of PCR-positive cells after high-dose therapy in
patients with t(14;18)-positive follicular lymphoma is also associ-
ated with a greater likelihood of relapse (Gribben et al, 1993).
In conclusion, patients with stage III disease and with ER-nega-
tive tumours have a poor prognosis despite sequential high-dose
therapy. Further intensification of the therapy by administering
additional cycles of high-dose therapy with non-cross-resistant
cytotoxic drugs is feasible, as we have shown for patients with
metastatic disease (Hohaus et al, 1998). Immunological treatment
modalities including the use of antibodies against antigens
expressed on the surface of breast cancer cells such as HER-
2/NEU, breast mucins or the epithelial glycoprotein 17-1A might
also be envisaged in conjunction with the high-dose therapy.
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